

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF TEXAS
TYLER DIVISION**

POZEN INC. Plaintiff, v. PAR PHARMACEUTICAL, INC. Defendant.	CIVIL ACTION NO. 6:08-cv-437-LED PATENT CASE
POZEN INC. Plaintiff, v. ALPHAPHARM PTY LTD. Defendant.	CIVIL ACTION NO. 6:09-cv-003-LED CONSOLIDATED WITH CIVIL ACTION NO. 6:08-cv-437-LED AND CIVIL ACTION NO. 6:09-cv-182-LED PATENT CASE
POZEN INC. Plaintiff, v. TEVA PHARMACEUTICALS USA, INC. Defendant.	CIVIL ACTION NO. 6:09-cv-182-LED CONSOLIDATED WITH CIVIL ACTION NO. 6:08-cv-437-LED AND CIVIL ACTION NO. 6:09-cv-003-LED PATENT CASE

**POZEN INC.'S UNOPPOSED MOTION
FOR LEAVE TO AMEND ITS ORIGINAL COMPLAINT**

Plaintiff Pozen Inc. ("Pozen"), unopposed by defendants Par Pharmaceutical, Inc. ("Par"), Alphapharm Pty Ltd. ("Alphapharm") and Teva Pharmaceuticals USA, Inc. ("Teva"), hereby moves the Court pursuant to Federal Rule of Civil Procedure 15 for an Order granting

Pozen leave to amend its Original Complaint.¹ The Amended Complaint was filed on August 21, 2009 [Docket 92]. Specifically, Pozen seeks to add Dr. Reddy's Laboratories, Inc. ("Dr. Reddy's") as a fourth defendant.² Pozen contends that Dr. Reddy's infringes all three of the patents currently asserted in this lawsuit.

Subsequent to filing the Amended Complaint, Pozen's counsel has conferred with counsel for Par, Alphapharm and Teva regarding this motion, and counsel for Par, Alphapharm and Teva have consented in writing, in accordance with Federal Rule of Civil Procedure 15(a)(2), to the filing of Pozen's Amended Complaint.

CONCLUSION

For the foregoing reasons, Pozen, unopposed by Par, Alphapharm and Teva, respectfully requests that this Court grant Pozen leave to amend its Original Complaint.

¹ Rule 15(a)(2) provides that, after a responsive pleading is served, as is the case here, "a party may amend its pleading only with the opposing party's written consent or the court's leave." FED. R. CIV. P. 15(a)(2). Moreover, this rule states that "[t]he court should freely give leave when justice so requires." *Id.*

² Pozen did not bring suit against Dr. Reddy's until this time because it did not receive notice of Dr. Reddy's petition to the FDA to market a generic version of Treximet™ before the expiration of United States Patent Nos. 6,060,499, 6,586,458 and 7,332,183, the patents-in-suit, until August 3, 2009.

Dated: September 1, 2009

Respectfully submitted,

/s/ Collin Maloney

Willem G. Schuurman (TX Bar No. 17855200)

Tracey B. Davies (TX Bar No. 24001858)

Stephen M. Hash (TX Bar No. 24012800)

Erin A. Thomson (TX Bar No. 24056433)

VINSON & ELKINS L.L.P.

The Terrace 7

2801 Via Fortuna, Suite 100

Austin, Texas 78746-7568

Tel: (512) 542-8400

Fax: (512) 236-3476

bschuurman@velaw.com

tdavies@velaw.com

shash@velaw.com

ethomson@velaw.com

Stephanie Lollo (NY Bar No. 4259149)

Rebecca Cantor (NY Bar No. 4698130)

VINSON & ELKINS L.L.P.

666 Fifth Avenue, 26th Floor

New York, New York 10103-0040

Tel: (212) 237-0032

Fax: (917) 849-5391

slollo@velaw.com

rcantor@velaw.com

Daniel L. Tobey (TX Bar No. 24048842)

VINSON & ELKINS L.L.P.

2001 Ross Avenue, Suite 3700

Dallas, Texas 75201-2975

Tel: (214) 220-7848

Fax: (214) 999-7848

dtobey@velaw.com

Otis W. Carroll, Jr. (TX Bar No. 03895700)

Collin Maloney (TX Bar No. 00794219)

IRELAND CARROLL & KELLEY, PC

6101 S. Broadway, Suite 500

Tyler, TX 75703

Tel: (903) 561-1600

Fax: (903) 581-1071

cmaloney@icklaw.com

Counsel for Plaintiff Pozen Inc.

CERTIFICATE OF CONFERENCE

The undersigned certifies that counsel for Plaintiff has conferred with opposing counsel regarding the filing of this motion and there is no opposition to the relief requested herein.

/s/ Collin Maloney

CERTIFICATE OF SERVICE

The undersigned certifies that the foregoing document was filed electronically in compliance with Local Rule CV-5(a). As such, this motion was served on all counsel who are deemed to have consented to electronic service. Local Rule CV-5(a)(3)(A). Pursuant to Fed. R. Civ. P. 5(d) and Local Rule CV-5(d) and (e), all other counsel of record not deemed to have consented to electronic service were served with a true and correct copy of the foregoing by email and/or fax, on this the 1st day of September, 2009.

/s/ Collin Maloney

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF TEXAS
TYLER DIVISION**

POZEN INC. Plaintiff, v. PAR PHARMACEUTICAL, INC. Defendant.	CIVIL ACTION NO. 6:08-cv-437-LED PATENT CASE
POZEN INC. Plaintiff, v. ALPHAPHARM PTY LTD. Defendant.	CIVIL ACTION NO. 6:09-cv-003-LED CONSOLIDATED WITH CIVIL ACTION NO. 6:08-cv-437-LED AND CIVIL ACTION NO. 6:09-cv-182-LED PATENT CASE
POZEN INC. Plaintiff, v. TEVA PHARMACEUTICALS USA, INC. Defendant.	CIVIL ACTION NO. 6:09-cv-182-LED CONSOLIDATED WITH CIVIL ACTION NO. 6:08-cv-437-LED AND CIVIL ACTION NO. 6:09-cv-003-LED PATENT CASE

**ORDER GRANTING POZEN INC.'S UNOPPOSED MOTION
FOR LEAVE TO AMEND ITS ORIGINAL COMPLAINT**

THE COURT, having considered Plaintiff Pozen Inc.'s Unopposed Motion for Leave to Amend its Original Complaint, and finding no objection to it and good cause for it, hereby grants the Unopposed Motion.

IT IS THEREFORE ORDERED that Pozen is granted leave to amend its Original

Complaint. The Amended Complaint filed by Pozen on August 21, 2009 [Docket 92] is thereby approved.